Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Madison, Wisconsin 53792


Primary objective is to determine the effectiveness of the combination of bortezomib and doxorubicin in patients with metastatic breast cancer. The trial format is a single arm Phase II design wherein patients are treated with bortezomib IV on days 1, 4, 8, and 11 and with doxorubicin IV on days 1 and 8 of a 21-day cycle.


Inclusion Criteria: - Cytologically or histologically confirmed metastatic breast cancer - Measurable or evaluable disease - Age > 18, PS 0,1,2 - MUGA > 45% - Received one or fewer chemotherapies or investigational regimens for metastatic disease, no limit to the number of prior hormonal therapies. May have had single agent Herceptin and/or Herceptin plus single-agent chemotx. - Must meet designated laboratory criteria within 14 days of enrollment Exclusion Criteria: - Doxorubicin for metatstatic disease. - Pregnant or lactating. - Active infections, no myocardial infarction within 2 months of enrollment. - Investigational drugs within 14 days of enrollment. - Chemotherapy, radiotherapy, hormonal therapy or other investigational therapy within 4 weeks of enrollment. - Neuropathy that is > grade 2. - Active brain mets. - Hypersensitivity to bortezomib, boron, or mannitol.



Primary Contact:

Principal Investigator
James A Stewart, M.D.
University of Wisconsin PPC Comprehensive Cancer Center

Backup Contact:


Location Contact:

Madison, Wisconsin 53792
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.